Lennert lymphoma

Lennert lymphoma
Synonyms	Lymphoepithelioid cell variant of peripheral T-cell lymphoma
Pronounce	N/A
Specialty	Hematology, Oncology
Symptoms	Lymphadenopathy, fever, weight loss, night sweats
Complications	N/A
Onset	Typically in adulthood
Duration	Chronic
Types	N/A
Causes	Unknown
Risks	Possible genetic predisposition, immunosuppression
Diagnosis	Biopsy, immunohistochemistry
Differential diagnosis	Hodgkin lymphoma, Non-Hodgkin lymphoma
Prevention	N/A
Treatment	Chemotherapy, radiation therapy, stem cell transplant
Medication	N/A
Prognosis	Variable, depends on stage and response to treatment
Frequency	Rare
Deaths	N/A

Lennert lymphoma is a rare subtype of T-cell lymphoma, characterized by the presence of lymphoepithelioid cells (Lennert cells) in the lymph nodes. It was first described by Karl Lennert and his colleagues in 1975.

Epidemiology

Lennert lymphoma is extremely rare, accounting for less than 1% of all non-Hodgkin lymphomas. It is more common in adults than in children, and there is no clear gender predominance.

Pathophysiology

The pathophysiology of Lennert lymphoma is not well understood. It is thought to arise from mature T cells, but the exact mechanism of transformation is unknown. The disease is characterized by the presence of large numbers of lymphoepithelioid cells, which are a type of histiocyte that has been transformed into a lymphocyte-like cell.

Clinical Features

Patients with Lennert lymphoma typically present with lymphadenopathy, fever, weight loss, and night sweats. The disease is often advanced at the time of diagnosis, with involvement of the bone marrow, liver, and spleen.

Diagnosis

The diagnosis of Lennert lymphoma is based on the histological examination of a lymph node biopsy. The characteristic finding is the presence of large numbers of lymphoepithelioid cells, which have a distinctive appearance under the microscope.

Treatment

The treatment of Lennert lymphoma is similar to that of other T-cell lymphomas. It typically involves chemotherapy, with or without radiation therapy. The prognosis is generally poor, with a median survival of less than 2 years.

See Also

• T-cell lymphoma
• Non-Hodgkin lymphoma
• Lymphadenopathy
• Karl Lennert

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia